A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Kura Oncology, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Columbia University
IGM Biosciences, Inc.
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins